Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH".
Zydus Lifesciences Limited Press Release Aug 31 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited announced positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH. The trial successfully met its primary endpoint of resolution of steatohepatitis without worsening fibrosis. These results contribute to the ongoing development program for Saroglitazar Mg, addressing a significant global health issue. The Managing Director highlighted the trial's completion as a milestone in developing innovative treatments for chronic liver diseases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Aug 21 2026
- Zydus Hospitals Sets New Benchmarks in High-Risk Pregnancy and Complex Gynaecological Care
- Zydus Lifesciences Limited Press Release Aug 11 2026
- Zydus Lifesciences Limited Press Release Aug 04 2026
- Zydus Lifesciences Limited Press Release Aug 01 2026
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Sep 26 2026
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad".
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences